Welcome to the Pentracor GmbH

Pentracor is a medical device company that has developed a breakthrough innovation for the treatment of acute myocardial infarction. Our first product on the German market is PentraSorb® CRP and has attracted much attention since the completion of a landmark clinical trial. Pentracor has a research and development pipeline in several therapeutic areas based on our unique expertise in immunology.

C-reactive protein (CRP) is an antibody of prehistoric immune systems and the innate immune system. It binds to proteins of the complement system forming immunocomplexes. In heart attack and stroke CRP increases primary damage. Further, the severity of rheumatic diseases is often determined by the amount of CRP.

The CRP adsorber (PentraSorb® CRP) is CE-marked. The corresponding Quality management system certificate according to EN ISO 13485 and the EC Certificate of Conformity in accordance with Directive 93/42/EEC are available.

More about the treatmentAsk questions

PentraSorb® CRP

Since November 2014 Pentracor GmbH is responsible and certified for the production and distribution of CRP adsorbers according to EN ISO 13485. The PentraSorb® CRP is an adsorber for the selective depletion of C-reactive protein (CRP).

CRP Adsorber

In the case of organ damage (e.g. heart attack or stroke), CRP marks cells capable of regeneration, which are then eliminated by the immune system. This increases the primary damage.

With the help of the PentraSorb® CRP can be removed from the blood with the aim of reducing this damage.

Read More

CRP apheresis

In CRP apheresis, CRP is selectively removed from the patient's blood plasma.

The application of PentraSorb® CRP is comparable to dialysis and can be performed in an outpatient or inpatient setting.

During the treatment, blood plasma is passed through the PentraSorb® CRP, which then selectively removes CRP from it.

Read More


In principle, CRP reduction can induce therapeutic benefits in a number of acute and chronic diseases.

PentraSorb® CRP is a potential therapeutic option for diseases where elevated CRP levels are associated with a poor prognosis.

Read More



Neue Publikation: CRP-Apherese bei cardiogenem Schock

11.12.2023 Im CAMI-Register werden die Daten von Herzinfarktpatienten gesammelt, die mit der CRP-Apherese behandelt wurden. In diesem Rahmen konnten auch Daten von Patienten mit cardiogenem Schock gewonnen werden. Die Ergebnisse der ersten 10 Patienten (9 wurden reanimiert) wurden nun in Frontiers in Drug Discovery veröffentlicht. Obwohl bei cardiogenem Schock mit einer hohen Krankenhausmortalität zu rechnen…

CRP-Apherese im medizinischen Alltag angekommen

10.12.2023 Im Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, einer der ältesten deutschen Fachzeitschriften im Bereich Arbeit, Umwelt, Gesundheit und Sicherheit, wurde ein Artikel über das C-reaktive Protein veröffentlicht. Dort wird unter anderem die schädliche Rolle des CRP bei ischämischen Vorfällen hervorgehoben und auch die CRP-Apherese als Therapiemöglichkeit genannt. Den Originalartikel C-reaktives Protein (CRP) – ein…

New publication: Being Eaten Alive


In tissues with insufficient oxygen supply, CRP initiates the disposal of vital cells. They are being eaten alive. This leads to damage, e.g. after heart attack. Therefore, CRP is obviously a therapeutic target molecule.

New publication about CRP as a target for therapy to reduce inflammation


Frontiers in Immunology published an article by three Canadian authors on CRP as a therapeutic target.

New publication on CRP apheresis as a therapeutic option in STEMI


The cardiac MRI tissue characteristics of myocardial damage correlate with the extent of left ventricular dysfunction in the acute phase of severe myocardial infarction (STEMI). Since lowering CRP levels leads to smaller infarcts and better heart function, it could be considered as an additional therapeutic option in STEMI.

Call for studies by the DCCV on CRP apheresis in Crohn's disease and ulcerative colitis  


The German Crohn's Disease / Ulcerative Colitis Association and the Federal Association for Chronic Inflammatory Diseases of the Digestive Tract (DCCV) e.V. are looking for study participants for the clinical study on the selective depletion of the C-reactive protein by means of therapeutic apheresis (CRP apheresis) in Crohn's disease and ulcerative colitis ( CAMCRO1).